AstraZeneca

AstraZeneca listed as one of the world's Top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage

23 Januari 2018 08:01

AstraZeneca ranked 34th in Corporate Knights’ 14th annual Global 100 list of the most sustainable companies in the world

AstraZeneca identified as “biggest achiever” alongside Bank of America, and Coca Cola Enterprises Inc. (now Coca Cola European Partners) for 300% increase in renewable electricity in a single year

AstraZeneca has been recognised for its commitment to sustainabi

Lynparza receives approval in Japan for the treatment of advanced ovarian cancer

19 Januari 2018 08:06

Lynparza is the first PARP inhibitor approved in Japan

Lynparza tablets approved as maintenance treatment for women with platinum-
sensitive relapsed ovarian cancer regardless of BRCA mutation status

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare has approv

Fasenra receives approval in Japan

19 Januari 2018 08:06

Approval based on Phase III WINDWARD programme that demonstrated significant
reductions in asthma exacerbations, improvements in lung functionand reductions in
oral corticosteroid use from baseline, versus placebo

Fasenra is the first approved respiratory biologic with an 8-week maintenance dosing schedule

AstraZeneca and its global biologics research and development arm,

Risk of repeat heart attack twice as likely from occlusions in arteries that did not cause initial event

16 Januari 2018 16:42

AstraZeneca announced today the publication of a new analysis from an ongoing real-world quality registry that suggests the risk of experiencing a repeat heart attack (also known as a myocardial infarction or MI) from occlusions in non-stentedarteries is twice as high as the risk stemming from the initially stented artery following a first heart attack.

Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer

12 Januari 2018 17:20

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),

Fasenra receives EU approval for severe eosinophilic asthma

10 Januari 2018 16:28

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.

US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer

18 December 2017 08:03

Acceptance follows FDA Breakthrough Therapy Designation
Tagrisso granted Priority Review
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of Tagrisso (osimertinib), a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity agains

AstraZeneca to highlight its commitment to blood cancers at the 2017 American Society of Hematology Annual Meeting

6 December 2017 08:02

AstraZeneca, along with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer research at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA

Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

4 December 2017 08:04

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.

The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer

28 November 2017 08:15

AstraZeneca today announced that the European Medicines Agency has accepted a variation to the Marketing Authorisation Application (MAAv) for Tagrisso (osimertinib),

AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China

27 November 2017 08:17

AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster.

AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan

27 November 2017 08:04

AstraZeneca today announced the submission of a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency for the use of Tagrisso (osimertinib).

Nyhetsarkiv